Article Information
History
- September 2, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Amihai Rottenstreich, MD1,*,
- Gila Zarbiv, RN, CNM1,
- Esther Oiknine-Djian, PhD2,
- Olesya Vorontsov, MSc2,
- Roy Zigron, MD1,
- Geffen Kleinstern, PhD3,
- Dana G. Wolf, MD2,* and
- Shay Porat, MD1
- 1Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel
- 2Clinical virology unit, Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
- 3School of Public Health, University of Haifa, Haifa, Israel
- ↵*Corresponding Authors:
Amihai Rottenstreich, MD, Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Center, POB 12000, Jerusalem, Israel, 91120. Tel: ++972-2-6779415; Fax ++972-2-6449580. amichaimd{at}gmail.com, Dana G. Wolf, MD, Clinical Virology Unit, Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, 91120, Tel: ++972-2-6777890; Fax: ++972-2-6427921 e-mail: dana.wolf{at}ekmd.huji.ac.il
Posted September 02, 2021.
Early versus late third trimester maternal SARS-CoV-2 BNT162b2 mRNA immunization maximizes transplacental antibody transfer and neonatal neutralizing antibody levels
